The Healthcare sector is made up of devices and systems that support healthcare organizations such as hospitals, doctor’s offices, surgical centers, and more. Healthcare technologies range from equipment like imaging machinery and robotic surgical assistants to patient recordkeeping applications and scheduling support. Register today to discover how Forge can help you buy and sell private shares.
Register to add companies to your watchlist and get access to bids/asks activity, last matched price and trade eligibility details.
Register| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4 |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids | $ Total Asks | # Bids | # Asks | Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
| Lumafield | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $148.24MM | Series C | 3/13/2025 | $75MM | $398.25MM | $7.34 | IVP, G2 Venture Partners, Wellington Management, Spark Capital, DCVC, Kleiner Perkins, Lux Capital, Matter Venture Partners | |||||
| Biolinq | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $275.18MM | Series C-1 | 4/22/2025 | $100MM | $397.31MM | $1.05 | Alpha Wave Ventures, RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical, Features Capital | |||||
| Truvian | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $204.13MM | Series D-1 Convertible | 7/17/2024 | $46.73MM | $396.91MM | $0.07 | Wittington Ventures, GreatPoint Ventures, DNS Capital, Medical Excellence Capital, Tao Capital, TYH Ventures, 7wireVentures | |||||
| Seismic Therapeutic | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $470.32MM | Series B | 12/4/2023 | $146.28MM | $396.35MM | $4.52 | Bessemer Venture Partners, Amgen Ventures, Codon Capital, Alexandria Venture Investments, Gaingels, GC&H, Timothy A. Springer, Lightspeed Venture Partners, Polaris Partners, Boxer Capital, GV, Samsara BioCapital | |||||
| Svelte Medical Systems | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $153.65MM | Series C | 4/23/2021 | $11.89MM | $396.2MM | $321.83 | Undisclosed Investors | |||||
| Elation Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $229.44MM | Series D | 7/26/2022 | $50MM | $395.27MM | $3.11 | Generation Investment Management, Ascension Ventures, Threshold Ventures, Ascend Partners, Fay Rotenberg, Jonathan Bush | |||||
| Clear Labs | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $157.08MM | Series D | 1/13/2025 | $30MM | $395.17MM | $2.80 | Counterpoint Global, Felicis, GV, HBM Genomics, Khosla Ventures, Menlo Ventures, Nimble Ventures, Redmile Group, Wing Venture Capital, T. Rowe Price Associates | |||||
| Elligo Health Research | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $213.37MM | Series E-1 | 9/23/2021 | $34.87MM | $392.04MM | $1.99 | Morgan Stanley Expansion Capital, Ally Bridge Group, Norwest Venture Partners, Cerner, Hatteras Venture Partners, Noro-Moseley Partners, Piper Sandler, Shumway Capital, Syneos Health | |||||
| Tenvie | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $200MM | Series A | 1/8/2025 | $158.05MM | $391.74MM | $1.00 | ARCH Venture Partners, F-Prime Capital, Mubadala Capital | |||||
| Medly Pharmacy | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $297.45MM | Series C-1 | 7/29/2022 | $51.86MM | $389.1MM | $0.20 | Undisclosed Investors | |||||
| Terray Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $201.97MM | Series B | 10/17/2024 | $120MM | $386.49MM | $6.66 | Bedford Ridge Capital, NVIDIA, Maverick Capital, Goldcrest Capital, Madrona Venture Group, Two Sigma Ventures, XTX Ventures, Digitalis Ventures, Alexandria Venture Investments | |||||
| VideaHealth | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $70.96MM | Series B-1 | 1/28/2025 | $40MM | $385.89MM | $20.34 | Emily Melton, Avenir, BAM Corner Point, Spark Capital, Zetta Venture Partners, Pillar VC | |||||
| Arthrosi Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $294.54MM | Series E | 10/8/2025 | $148.1MM | $385.03MM | $6.54 | Prime Eight Capital, CR Biotech, HighLight Capital, HM Venture Partners, ReliantTech | |||||
| Calibrate | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $97.15MM | Series B | 8/25/2021 | $76.9MM | $382.73MM | $5.35 | Founders Fund, Tiger Global Management, Optum Ventures, Threshold Ventures, Forerunner Ventures, Redesign Health | |||||
| Nalu | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $331.77MM | Series E | 10/9/2024 | $115.06MM | $382.56MM | $4.85 | Novo Holdings, Gilde Healthcare, MVM Partners, Endeavour Vision, Decheng Capital, Longitude Capital, Advent Life Sciences, Pura Vida, Aperture Venture Partners, B Capital | |||||
| Eden Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $98.78MM | Series C | 2/18/2021 | $60MM | $382.34MM | $4.67 | Insight Partners, Amigos Health, Aspect Ventures, Company Ventures, Flare Capital, Flexcap Ventures, Max Ventures, PJC | |||||
| MediBeacon | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $110.73MM | Series 3 | 12/7/2023 | $30.18MM | $381.55MM | $72.00 | Undisclosed Investors | |||||
| Tomorrow Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $92.06MM | Series B | 6/29/2022 | $60MM | $380.93MM | $8.96 | BOND, Andreessen Horowitz, Obvious Ventures, BoxGroup, Sound Ventures | |||||
| Attovia | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $255.85MM | Series C | 4/15/2025 | $90MM | $378.97MM | $1.38 | Deep Track Capital, Vida Ventures, Sanofi Ventures, Mirae Asset Capital Life Science, Frazier Life Sciences, venBio, Goldman Sachs, Nextech Ventures, Cormorant Asset Management, EcoR1 Capital, Marshall Wace, Illumina Ventures | |||||
| Prosetta Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $63.64MM | Series D | 12/31/2015 | $31.1MM | $378.68MM | $4.50 | Takeda Ventures, Alger | |||||
| Arcellx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $235.48MM | Series C | 4/13/2021 | $120MM | $377.76MM | $2.10 | Samsara BioCapital, CAM Capital, Adage, Asymmetry, CaaS Capital, Cambrian Bio, Sixty Degree, Soleus Capital, Surveyor Capital, Suvretta, Terra Magnum Capital Partners, New Enterprise Associates, Novo Holdings, SR One, Takeda Ventures, LG Tech, Clough Capital | |||||
| TriSalus Life Sciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $198.81MM | Series B-2 | 10/5/2022 | $15.32MM | $375.88MM | $0.35 | Undisclosed Investors | |||||
| ArriVent Biopharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $260MM | Series B | 12/16/2022 | $110MM | $375.08MM | $1.05 | Undisclosed Investors | |||||
| Akido | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $106.75MM | Series B | 5/15/2025 | $60MM | $373.15MM | $13.45 | Oak HC/FT, Greco, SNR, Y Combinator, Future Communities Capital, Jeff Dean, Comprehensive Blood & Cancer Center | |||||
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
Post-Money Valuation (valuation) represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions.
Sector and subsector descriptions focus primarily on the types of companies within the respective sectors and subsectors that are typically available through Forge Markets. Any sector or subsector as a whole may include companies that participate in business lines in other sectors or subsectors. Companies are classified into sectors and subsectors according to the problem(s) they seek to solve rather than the method by which the solution is delivered.